Carboplatin and paclitaxel in advanced or metastatic endometrial cancer-Reference-Cited by-同舟云学术

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

Published:2008-05 Issue:2 Volume:109 Page:250-254
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Pectasides D.,Xiros N.,Papaxoinis G.,Pectasides E.,Sykiotis C.,Koumarianou A.,Psyrri A.,Gaglia A.,Kassanos D.,Gouveris P.,Panayiotidis J.,Fountzilas G.,Economopoulos T.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference24 articles.

1. Cancer Statistics, 2007

2. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;Cancer Treat Rep,1979

3. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;J Clin Oncol,1994

4. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study;Thigpen;Gynecol Oncol,1989

5. Cisplatin chemotherapy for disseminated endometrial cancer;Seski;Obstet Gynecol,1982

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus;Gynecologic Oncology;2024-11

2. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis;International Journal of Gynecologic Cancer;2024-06-20

3. Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma;Cancers;2024-05-30

4. The efficacy and safety of the novel combination lenvatinib and pembrolizumab in endometrial cancer: A systematic review and single-arm meta-analysis;Heliyon;2024-05

5. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial;Journal of Clinical Oncology;2024-01-20